354 related articles for article (PubMed ID: 28170394)
1. Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada.
Ten Haaf K; Tammemägi MC; Bondy SJ; van der Aalst CM; Gu S; McGregor SE; Nicholas G; de Koning HJ; Paszat LF
PLoS Med; 2017 Feb; 14(2):e1002225. PubMed ID: 28170394
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
3. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.
Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A
BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313
[TBL] [Abstract][Full Text] [Related]
4. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.
de Koning HJ; Meza R; Plevritis SK; ten Haaf K; Munshi VN; Jeon J; Erdogan SA; Kong CY; Han SS; van Rosmalen J; Choi SE; Pinsky PF; Berrington de Gonzalez A; Berg CD; Black WC; Tammemägi MC; Hazelton WD; Feuer EJ; McMahon PM
Ann Intern Med; 2014 Mar; 160(5):311-20. PubMed ID: 24379002
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.
Meza R; Jeon J; Toumazis I; Ten Haaf K; Cao P; Bastani M; Han SS; Blom EF; Jonas DE; Feuer EJ; Plevritis SK; de Koning HJ; Kong CY
JAMA; 2021 Mar; 325(10):988-997. PubMed ID: 33687469
[TBL] [Abstract][Full Text] [Related]
7. Biennial lung cancer screening in Canada with smoking cessation-outcomes and cost-effectiveness.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
Lung Cancer; 2016 Nov; 101():98-103. PubMed ID: 27794416
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of Lung Cancer Screening in Canada.
Goffin JR; Flanagan WM; Miller AB; Fitzgerald NR; Memon S; Wolfson MC; Evans WK
JAMA Oncol; 2015 Sep; 1(6):807-13. PubMed ID: 26226181
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
10. Risk-Targeted Lung Cancer Screening: A Cost-Effectiveness Analysis.
Kumar V; Cohen JT; van Klaveren D; Soeteman DI; Wong JB; Neumann PJ; Kent DM
Ann Intern Med; 2018 Feb; 168(3):161-169. PubMed ID: 29297005
[TBL] [Abstract][Full Text] [Related]
11. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
Mahadevia PJ; Fleisher LA; Frick KD; Eng J; Goodman SN; Powe NR
JAMA; 2003 Jan; 289(3):313-22. PubMed ID: 12525232
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study.
Du Y; Sidorenkov G; Heuvelmans MA; Groen HJM; Vermeulen KM; Greuter MJW; de Bock GH
Eur J Cancer; 2020 Aug; 135():121-129. PubMed ID: 32563896
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.
Tomonaga Y; Ten Haaf K; Frauenfelder T; Kohler M; Kouyos RD; Shilaih M; Lorez M; de Koning HJ; Schwenkglenks M; Puhan MA
Lung Cancer; 2018 Jul; 121():61-69. PubMed ID: 29858029
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening.
Toumazis I; de Nijs K; Cao P; Bastani M; Munshi V; Ten Haaf K; Jeon J; Gazelle GS; Feuer EJ; de Koning HJ; Meza R; Kong CY; Han SS; Plevritis SK
JAMA Oncol; 2021 Dec; 7(12):1833-1842. PubMed ID: 34673885
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of lung MRI in lung cancer screening.
Allen BD; Schiebler ML; Sommer G; Kauczor HU; Biederer J; Kruser TJ; Carr JC; Hazen G
Eur Radiol; 2020 Mar; 30(3):1738-1746. PubMed ID: 31748855
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of computed tomography screening for lung cancer in the United States.
McMahon PM; Kong CY; Bouzan C; Weinstein MC; Cipriano LE; Tramontano AC; Johnson BE; Weeks JC; Gazelle GS
J Thorac Oncol; 2011 Nov; 6(11):1841-8. PubMed ID: 21892105
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of low-dose CT screening for lung cancer: preliminary results of baseline screening.
Wisnivesky JP; Mushlin AI; Sicherman N; Henschke C
Chest; 2003 Aug; 124(2):614-21. PubMed ID: 12907551
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of implementing computed tomography screening for lung cancer in Taiwan.
Yang SC; Lai WW; Lin CC; Su WC; Ku LJ; Hwang JS; Wang JD
Lung Cancer; 2017 Jun; 108():183-191. PubMed ID: 28625633
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
